Nivolumab‐associated myositis myocarditis and myasthenia and anti‐striated muscle antibodies.
- Resource Type
- Article
- Authors
- Fazal, Marium; Prentice, David A.; Kho, Lay K.; Fysh, Edward
- Source
- Internal Medicine Journal. Aug2020, Vol. 50 Issue 8, p1003-1006. 4p. 1 Black and White Photograph.
- Subject
- *ANTINEOPLASTIC agents
*APOPTOSIS
*BIOMARKERS
*BLOOD gases analysis
*CANCER relapse
*DISEASE complications
*IMMUNOGLOBULINS
*IMMUNOTHERAPY
*MELANOMA
*MUSCLES
*MYASTHENIA gravis
*CARDIOMYOPATHIES
*MYOSITIS
*TREATMENT effectiveness
- Language
- ISSN
- 1444-0903
An 82‐year‐old man was treated with neo‐adjuvant nivolumab (programmed cell death protein 1 or PD‐1 inhibitor) for local recurrence of melanoma developed myositis, myocarditis and a myasthenic‐like syndrome with a fatal outcome. The occurrence of these three conditions may constitute a new immune checkpoint‐induced syndrome. The relevance of the clinical features and the immunology is discussed. This case highlights the special role of anti‐striated muscle antibodies as a predictor of mortality. [ABSTRACT FROM AUTHOR]